> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Quest CEO Says New Medicare Data Shows Independent Labs Skew Lab-Fee Cuts
- URL: https://www.bullished.co/quest-ceo-says-new-medicare-data-shows-independent-labs-skew-lab-fee-cuts-697fa67d/
- Published: 2026-10-22T14:06:01.000Z
- Updated: 2026-10-29T19:08:32.000Z
- Description: Jim Davis says independent labs supplied 76.5% of reported volume, and Quest wants Congress to pass the Results Act by year-end.
- Author: Matteo Parrino
- Tags: Earnings, DGX, Industry: Healthcare

[Quest Diagnostics](https://www.bullished.co/tag/dgx/) CEO Jim Davis said on the company's third-quarter earnings call Thursday that federal data released a day earlier shows independent labs supplied [76.5% of the volume](https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx093020268-kex991.htm?ref=bullished.co) reported for setting 2027 Medicare lab fees. Hospital outreach labs supplied under 10%, a mix he said "emboldens us even further to push fast and furious for the Results Act."

## A Sample Davis Calls Lopsided

Quest, which provides laboratory testing to physicians, hospitals, patients and health plans, is one of the labs facing fee cuts under PAMA, the 2014 law that resets Medicare lab prices from lab-reported market data. Davis, who is Quest's chairman, president and chief executive, said the Centers for Medicare & Medicaid Services released the breakdown of volume by lab type on Wednesday, after Quest had pushed for it.

In the previous survey, he said, over 90% of the data came from independent labs, which "surely do not have 90% share of this market." With hospital outreach volume so thin, he argued, the volume-weighted median shifts "way to the left."

He called the collection process flawed. Labs had to submit data a second time in 2026 after what he described as six years of congressional delays.

## 1,500 Codes Face Cuts

Davis said about 1,500 billing codes will get some reduction, 775 of them the maximum 15% cut. About 1,200 codes in total get cut, with roughly 400 to 500 of those facing less than 15%. "We didn't expect the data process to come out this way," he said.

An analyst at Barclays asked why the headwind now looks larger than the $100 million impact Davis had mentioned at a recent conference. Davis replied that Quest had always used a range of $100 million to $120 million before the data came out.

Chief Financial Officer Sam Samad said the 2027 PAMA impact is about 1% of total revenue, and the cumulative hit for 2027 through 2029 is expected to be under 1.3%. Quest intends to offset part of it, he said, but not by touching growth drivers, frontline staff or lab operations. Davis said not all of it will reach the bottom line, noting about $1 billion of costs outside the work of producing patient results.

## The Push For The Results Act

The bipartisan Results Act would permanently reform how PAMA data is collected. Davis said it has over 135 co-sponsors in Congress, and Quest and the American Clinical Laboratory Association want it included in a year-end healthcare package.

The next step is a Congressional Budget Office score, which Davis said he has been told to expect in mid-to-late November. After that, he said, the House Ways and Means, House Energy and Commerce and Senate Finance committees would need to act. He could not give odds on inclusion and said Quest would push for another PAMA delay if the Results Act stalls.

The quarter itself was strong: revenue rose 10% to $3.1 billion, adjusted earnings per share were $3.00 against $2.60 a year earlier, and the company raised its full-year guidance, Samad said. Quest will give 2027 guidance, including PAMA offsets, with fourth-quarter results early next year.

Quest's 2027 Investor Day is set for March 25 at the New York Stock Exchange, where it plans to lay out its long-term outlook.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Document](https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx093020268-kex991.htm?ref=bullished.co) — sec.gov
- [Quest Diagnostics: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/quest-diagnostics-q3-earnings-snapshot/616-e371d4d6-0b6f-4000-a888-2f25446ccfc5?ref=bullished.co) — Associated Press
- [A new at-home HPV test kit is going national through Quest Diagnostics - Fast Company](https://www.fastcompany.com/91626290/a-new-at-home-hpv-test-kit-is-going-national-through-quest-diagnostics?ref=bullished.co) — fastcompany.com
- [Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option](https://finance.yahoo.com/healthcare/articles/waters-corporation-quest-diagnostics-help-120000590.html?ref=bullished.co) — Yahoo Finance
- [Quest Diagnostics Non-GAAP EPS of $3.00 beats by $0.13, revenue of $3.1B beats by $50M (DGX:NYSE)](https://seekingalpha.com/news/4655789-quest-diagnostics-non-gaap-eps-of-3%5F00-beats-by-0%5F13-revenue-of-3%5F1b-beats-by-50m?ref=bullished.co) — seekingalpha.com

### More on Quest Diagnostics

- [Quest Diagnostics Sets Aside $32 Million For Legal Claims As Data-Breach Suits Near A Settlement](https://www.bullished.co/quest-diagnostics-sets-aside-32-million-for-legal-claims-as-data-breach-suits-near-a-6f65f2e4/)
- [Quest Diagnostics Lifts 2026 Revenue Outlook To $12.065 Billion–$12.105 Billion As Test Orders Climb 14.5%](https://www.bullished.co/quest-diagnostics-lifts-2026-revenue-outlook-to-12-065-billion-12-105-billion-as-test-c6769cbf/)
- [Quest Diagnostics Says Unauthorized Party Reached Patient Records In Quanum LSM Client System](https://www.bullished.co/quest-diagnostics-says-unauthorized-party-reached-patient-records-in-quanum-lsm-client-485d2444/)

[All Quest Diagnostics (DGX) coverage →](https://www.bullished.co/tag/dgx/)